-
2022-501901-10-00
6
2023-02-06
Chronic Hepatitis D Infection
-
2024-516168-27-00
5
2022-11-10
Adult patients with persistent or chronic immune thrombocytopenia
-
2024-513649-35-00
5
2022-09-15
Asplenia
-
2023-507964-38-00
5
2022-09-01
Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutate
-
2023-507131-38-00
5
2022-05-16
Neovascular Age-Related Macular Degeneration (nAMD)
-
2024-516403-16-00
5
2022-04-07
Adult patients with immune thrombocytopenia (ITP) with mild to severe
-
2023-506867-33-01
4
2022-01-25
Chronic Hepatitis B
-
2024-515739-32-00
4
2022-01-10
HBV
-
2023-508248-23-00
5
2021-11-26
Non-alcoholic steatohepatitis (NASH)
-
2023-507130-24-00
5
2021-10-22
Neovascular age-related macular degeneration (nAMD)
-
2024-516651-41-00
5
2021-10-08
COPD : chronic obstructive Pulmonary disease
-
2022-502047-35-00
4
2021-10-07
Yellow fever
-
2024-511753-22-00
5
2021-05-26
Primary Biliary Cholangitis
-
2024-511658-28-01
5
2021-04-06
primary sclerosing cholangitis
-
2023-506962-30-00
5
2021-03-29
Non-alcoholic steatohepatitis (NASH)
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2024-514104-14-00
4
2020-11-04
Adults subjects with advanced malignant pleural (cohort A) or peritone
-
2024-516673-68-00
5
2020-10-27
Human papillomavirus (HPV)-positive oropharyngeal cancer
-
2023-508635-31-00
5
2019-12-03
Hepatocellular Carcinoma
-
2024-510626-89-00
5
2019-11-18
Non-Alcoholic Steatohepatitis (NASH)
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2024-512667-31-00
5
2019-04-23
Main cohort: Patients with unresected Stage I/II, lymph-node negative
-
2024-510605-28-00
5
2018-11-27
Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
-
2024-513027-16-00
4
2018-05-28
Resectable mucosal melanomas